ISPOR - PCN22 Cost-Effectiveness of Pembrolizumab PLUS Axitinib Versus Nivolumab PLUS Ipilimumab As First-LINE Treatment of Advanced Renal CELL Carcinoma

PCN22 Cost-Effectiveness of Pembrolizumab PLUS Axitinib Versus Nivolumab PLUS Ipilimumab As First-LINE Treatment of Advanced Renal CELL Carcinoma

Abstract

Authors

C.Y. Kong X. Gao T. Watson K.L. Reynolds

Full Text Cite This Article

Back to Volume 22, Supplemental S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now